A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation.
J Cancer Res Ther
;
2005 Jan-Mar; 1(1): 38-40
Article
in English
| IMSEAR
| ID: sea-111401
ABSTRACT
PURPOSE:
To evaluate Tocoferol monoglucoside (TMG), a water soluble vit. E. in a phase I trial, as a radiation protector in those undergoing hemi-body radiation for disseminated disease. MATERIALS ANDMETHODS:
Patients scheduled to receive modified hemi-body radiation were accrued for the study. Patients not only had disseminated skeletal disease but, were heavily pretreated Seven patients were accrued for the study. Patients received 1 and 2 gms of TMG. 30-40 minutes before hemibody radiation. A dose of 600 cGy was delivered on telecobalt equipment at mid plane. Immediate Toxicities were evaluated as well as response to pain.RESULTS:
All the seven patients underwent radiation uneventfully. There was no drug related toxicity. Pain relief was adequate.CONCLUSION:
Tocoferol monoglucoside an effective antioxidant with no significant acute toxicity, when administered in a dose of 1 or 2 gms per oral route. TMG being water-soluble can have global antioxidant and radio protective effects. This needs further clinical evaluation.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Prostatic Neoplasms
/
Radiation-Protective Agents
/
Breast Neoplasms
/
Aged
/
Humans
/
Male
/
Hemibody Irradiation
/
Adult
/
Tocopherols
/
Glucosides
Language:
English
Journal:
J Cancer Res Ther
Journal subject:
Neoplasms
/
Therapeutics
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS